Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds

With Neuron23, Westlake Unveils Second Start-Up In A Week

Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns. 

Finance Watch

Biopharmaceutical companies developing therapies for neurological diseases are in the midst of a boom, not only in terms of novel approaches to treating intractable diseases but also in terms of attracting large sums of money to fund their research and development programs. Neuron23 Inc., Neurogene Inc. and Locanabio, Inc. each recently revealed new funding totaling $100m or more to fund R&D for neurological and other diseases.

Investors and biopharma executives frequently observe that this is neurology’s heyday, including newly named Sage Therapeutics, Inc. CEO Barry...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.